February 4, 2026

#16 - Sharing the Inside View: Reflections from the USD Discovery District Team

Listen and subscribe on your favorite platform

In this episode of Favorable Environments, Host Tung Nguyen speaks with fellow members of theUSD Discovery District leadership team—Ryan, President; Marc, Director of Biotech Development; in a reflective discussion—about the organization’s first operational year since taking possession of Building 1 in January 2025. The team shares candid insights into the milestones achieved, the challenges navigated, and the strategic pivots that have positioned the District as a purpose-built hub for bioscience and life sciences innovation in Sioux Falls.

The conversation explores the pragmatic realities of building a research park from the ground up: from refining tenant profiles to prioritize research-oriented companies, to developing a resource-mapping platform that connects prospects with statewide assets in academia, healthcare, and industry. Ryan, Marc, and Tung reflect on lessons from early tenant engagements, the value of an abundance mindset in partnerships, and how South Dakota’s low-density networks and statewide support create scalable advantages for commercialization and long-term growth. They discuss the importance of relationships as infrastructure—beyond buildings—and how collaborations with entities such as the University of South Dakota, Forward Sioux Falls, and regional healthcare systems drive momentum.

Later in the episode, the team addresses the cultural evolution of a small, agile group, the need for disciplined filtering of opportunities, and the vision for future phases, including alpha and beta testing of the resource-mapping tool and its potential as a standalone platform. The discussion highlights why the USD Discovery District serves as a conduit between university research, private sector ambition, and community impact, advancing applied research, talent pipelines, and bioscience scaling in a region built for resilience.

This episode provides an inside look at the disciplined progress behind South Dakota’s emerging bioscience campus and why the USD Discovery District continues to create favorable environments for mission-driven innovation, partnerships, and economic impact.

To stay connected with the USD Discovery District, follow us on LinkedIn at linkedin.com/company/usd-discovery-district and discover opportunities at usddiscovery.com, including leasing at Building 1 for research, diagnostics, and advanced manufacturing.

 

Favorable Environments is presented by the USD Discovery District and supported by South Dakota First Capital, working to expand access to capital for companies building the future of bioscience in the region.

About this Guest

USD Discovery District

Ryan Oines leads the USD Discovery District as President and CEO, driving economic growth through biotech and life sciences innovation. With over 25 years of experience launching startups and securing capital, he oversees a $314M development plan for 26 buildings, fostering 2,800 jobs. His strategic vision strengthens public-private partnerships, positioning South Dakota as a hub for research and commercialization.

Marc Niamba advances the USD Discovery District’s mission to pioneer life sciences innovation. As a key contributor to GreenLight Bionics, he leverages virtual reality to enhance physical therapy solutions, earning recognition in the 2021 Governor’s Giant Vision Competition. His expertise in computer science and artificial intelligence has enabled him to create internal management and tenant recruitment tools.

Tung Nguyen amplifies the USD Discovery District’s vision of innovation and economic impact. With a background in mechanical engineering and regulatory strategy, he crafts data-driven campaigns to attract biotech tenants and showcase the District’s $23MM funded private public partnership. Nguyen’s strategic storytelling connects academia, industry, and government, driving engagement and growth across South Dakota’s life sciences ecosystem.

Explore Other Episodes

#10 – Max Ostermeier: Minimizing Uncertainty

Max G. Ostermeier (MBA) is the co-founder and General Manager of Implandata Ophthalmic Products GmbH. He brings extensive experience in the commercial development of advanced technologies, building operational capabilities for rapidly growing companies, and creating businesses that attract global acquirers.

As a serial entrepreneur, Max founded and managed Odicrain GmbH, a German medical device start-up that developed a pioneering portable device for the rapid detection of intracranial bleedings, which was acquired by a US-based company in 2007. He also co-founded and served as CEO of Cranium Telemetrics GmbH, a medical technology company specializing in innovative neurosurgical products, which was acquired by a leading US medical device company four years after its founding. Additionally, Max played a key role in establishing a biotech entity for a globally leading fine chemistry company, where he served as General Manager and Vice-President until its acquisition by Sigma Aldrich.

Read More »

#6 – Mark Christopherson: Persevering Through The Doubters

This podcast episode features a conversation with Mark Christopherson. Mark Christopherson brings over three decades of expertise to the forefront of the medical device industry, with pivotal roles at Medtronic and leadership in venture-backed startups. Mark’s track record includes foundational roles at Inspire Medical and Cryosa, where he was instrumental from the startup phase through commercialization.

Read More »

#18 – Ian Weimer: Unlocking Value Through Real World Evidence in the New FDA Era

Ian Weimer brings over eight years of experience in data science, research, and business development to healthcare and life sciences analytics. After receiving his MS in Data Science from DePaul University, Ian spent three years as a data scientist at a boutique healthcare consultancy, leading analytics projects for Fortune 500 pharmaceutical and medical device companies.

His work contributed to 16 research publications and abstracts at leading conferences, supporting regulatory submissions and market access strategies with real-world evidence.

He founded Weimer Analytics in 2025 to serve clients from Fortune 500 to emerging companies across pharma, med device, and biotech. Weimer Analytics delivers health economics, real-world evidence, and regulatory analytics solutions.

Read More »

Join our newsletter for regular updates on the podcast, USD Discovery District, and medtech and life science related insights.

By submitting your email to subscribe, you agree to our Privacy Policy.

Proudly Sponsored By